Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Peking Union Medical College Hospital ( Site 0108), Beijing

Cancer Hospital Chinese Academy of Medical Science ( Site 0117), Beijing

Beijing Cancer Hospital ( Site 0120), Beijing

Jilin Cancer Hospital ( Site 0115), Changchun

The Third Affiliated Hospital of Harbin Medical University ( Site 0100), Harbin

Zhongshan Hospital Fudan University ( Site 0103), Shanghai

Shanghai Pulmonary Hospital ( Site 0101), Shanghai

Tianjin Medical University Cancer Institute & Hospital ( Site 0111), Tianjin

The First Affiliated Hospital Zhejiang University ( Site 0109), Hangzhou

Zhejiang Cancer Hospital ( Site 0113), Hangzhou

The First Affiliated Hospital of Wenzhou Medical University ( Site 0124), Wenzhou

Fujian Provincial Cancer Hospital ( Site 0102), Fuzhou

The Second Hospital Affiliated to AMU ( Site 0119), Chongqing

First Affiliated Hospital of The Third Military Medical University ( Site 0118), Chongqing

Wuhan Union Hospital ( Site 0123), Wuhan

Hubei Cancer Hospital ( Site 0122), Wuhan

Henan Cancer Hospital ( Site 0112), Zhengzhou

Southern Medical University Nanfang Hospital ( Site 0121), Guangzhou

Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110), Urumuqi